Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

Ingrezza (valbenazine) is a brand-name drug that’s prescribed for specific movement disorders in adults. Ingrezza comes as a capsule that’s typically taken once per day. Ingrezza is approved ...

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...

Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...

Investing.com -- Neurocrine Biosciences (NASDAQ: NBIX)股价下跌11%，原因是公司报告的营收未达预期。尽管2024年全年INGREZZA®（valbenazine）净产品销售额同比增长26%，但公司对2025年的业绩指引令投资者失望。

周五，Canaccord Genuity调整了对Neurocrine Biosciences股票的展望，将目标价从此前的172美元下调至163美元，同时维持买入评级。此次调整是基于对公司主打产品Ingrezza销售预期的重新评估。该公司目前股价为150.51美元，根据 InvestingPro ...